BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-04-25 15:49 |
Financial calendar
|
English | 644 bytes | ||
| 2023-04-25 15:48 |
BerGenBio ASA: Proposed partially underwritten rights issue
|
English | 109.6 KB | ||
| 2023-04-25 15:48 |
BerGenBio ASA: Foreslår delvis garantert fortrinnsrettsemisjon
|
Norwegian | 112.7 KB | ||
| 2023-04-25 15:48 |
BerGenBio ASA: Proposed partially underwritten rights issue
|
English | 18.4 KB | ||
| 2023-04-25 15:48 |
BerGenBio ASA: Foreslår delvis garantert fortrinnsrettsemisjon
|
Norwegian | 18.0 KB | ||
| 2023-04-18 05:00 |
BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR
|
English | 129.2 KB | ||
| 2023-04-18 05:00 |
BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR
|
English | 4.8 KB | ||
| 2023-03-29 18:39 |
Financial calendar
|
English | 644 bytes | ||
| 2023-03-28 06:00 |
BerGenBio to Present at Upcoming Scientific Conferences
|
English | 4.4 KB | ||
| 2023-03-16 06:00 |
BerGenBio to Present at the Carnegie Nordic Healthcare Conference
|
English | 102.7 KB | ||
| 2023-03-16 06:00 |
BerGenBio to Present at the Carnegie Nordic Healthcare Conference
|
English | 2.5 KB | ||
| 2023-03-09 10:00 |
BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcent…
|
English | 130.6 KB | ||
| 2023-03-09 10:00 |
BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcent…
|
English | 4.6 KB | ||
| 2023-02-16 06:00 |
BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business U…
|
English | 6.5 MB | ||
| 2023-02-16 06:00 |
BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business U…
|
English | 12.8 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
